LATEST NEWS IN PROSTATE CANCER
Video: The Sky (Newly Diagnosed) Stage
The Sky stage of prostate cancer means a PSA less than 10, a Gleason under 7, and no large tumor masses detected on digital rectal or on MRI. But we call Sky cancer. Interestingly, is it actually a cancer?
Video: The Five Stages of Prostate Cancer
Today we're going to talk about the five stages of prostate cancer. The PCRI has developed a system for patients. Prostate cancer is very complex. Who has time to study the full range of all the information associated with prostate cancer?
Prostate Digest | Spring 2018, Volume 21, Issue 1
The Prostate Cancer Research Institute is delighted to announce Prostate Digest, the new format for what was formerly Prostate Insights Magazine. Prostate Digest still contains articles from the most prestigious doctors in the field, clinical researchers, support group leaders, and PCRI’s staff. However, Prostate Digest comes in a newspaper! As before, we offer all articles online. If you prefer, you can receive articles directly to your email. Enter your email here or call us at 310-743-2116. To learn more about PCRI, our Medical Review Board, and our Board of Directors, click here.
The UnCancer
At the first ever Active Surveillance Convention, a conference I attended back in 2007, many experts openly bemoaned that the word “CANCER” profoundly overstates the significance of Gleason 6 type of prostate cancer. The pathologists at the conference, however, shot down the idea of a name change saying, “Under the microscope it looks like a cancer, so it is cancer.” No one at the conference had a rebuttal so the proposal for a name change was dropped.
Prostate Insights Quarterly Newsletter | Winter 2017, Volume 20, Issue 4
Hello Researcher, welcome to a new issue of Prostate Insights, a newsletter that brings you the latest information about prostate cancer. In addition to arresting the progress of cancer growth, it is of equal if not--in some cases--of more importance to focus on quality of life issues that arise as a result of one's treatment choice.
Prostate Insights Quarterly Newsletter | Volume 20, Issue 1
Hello Researcher, welcome to a new issue of Prostate Insights, a newsletter that brings you the latest information about prostate cancer. In addition to arresting the progress of cancer growth, it is of equal if not--in some cases--of more importance to focus on quality of life issues that arise as a result of one's treatment choice.
Erections Lasting 4 Hours and Other Emergencies
Since prostate cancer is predominantly a slow growing and asymptomatic disease, emergencies directly caused by prostate cancer are relatively rare. But there are a few conditions that can arise and it is good to be aware of them. Dr. Scholz highlights a few of these emergency conditions.
Abstracts from the 2016 AUA Meeting
AUA is an annual meeting of urologists where data from new studies are presented. This data is presented in abstracts, or summaries of the entire peer reviewed articles. In this article, Mark Scholz, MD, analyzes the data and explains the practical implications of these new studies.
Androgen Deprivation Therapy for Prostate Cancer Causes Alzheimer’s Disease?
Dr.Kevin Nead authored an article published in the Journal of Clinical Oncology this month. It created a media sensation and generated multiple calls to the PCRIHelpline. Last week, three separate articles about this topic were posted on the Yahoo home page at the same time.
What’s Going On at the Prostate Cancer Research Institute
In 2016, the PCRI will celebrate its 20th anniversary. The PCRI, founded in 1996 by Dr. Stephen Strum and I, was originally funded by a generous grant from the Daniel Freeman Medical Foundation. This initial grant was spent on hiring Harry Pinchot, aka Helpline Harry. The helpline format adopted at the PCRI was modeled after the work of Lloyd Ney, the founder of PAACT. PCRI’s helpline presently has four counselors: Jonathan Levy, Silvia Cooper, Bob Each and Charles Kokaska, all who provide unbiased prostate-cancer-related information, free of charge to the public.